Skip to main content
. 2022 Apr 22;17(4):e0266707. doi: 10.1371/journal.pone.0266707

Fig 5. Progression free survival (PFS) rates of the HAIC and standard chemotherapy cohorts.

Fig 5

The PFS rates were 20.0% and 25.2% at 6 months and 20.0% and 6.3% at 1 year, respectively. The median PFS was 3.7 months (95% CI 1.69–5.71) and 2.5 months (95% CI 1.76–3.31), respectively. There was no significant difference in PFS since found to be refractory to GC therapy between the HAIC and standard chemotherapy cohorts (P = 0.265).